Amiloride Hydrochloride as an Effective Treatment for ADHD
Sponsored by State University of New York - Upstate Medical University
The investigators are proposing to test a medication derived from our prior studies of the gene SLC9A9. This one gene makes NHE proteins that control how we learn and remember items, which is impaired in ADHD and may cause an inability to plan, prioritize, self-monitor,inihibit, initiate, self-correct, or control one's behavior. The investigators now propose to investigate the therapeutic utility of an NHE inhibitor, amiloride hydrochloride, for the treatment of attention deficit hyperactivity disorder (ADHD) in medication-naïve adults with ADHD.
Medication naïve male or female adults ages 18-45 years
A diagnosis of DSM-IV ADHD combined type based on clinical assessment by the study psychiatrist using the Conners Adult ADHD Diagnostic Interview
Proficiency in English
A baseline score of 24 or more on the AISRS
Ability to swallow pills
bility to report reliably, understand the nature of the study and sign an informed consent document as determined by the study psychiatrist
We will exclude potential participants who:'
Have had pharmacologic treatment for ADHD in the past year
Are pregnant or nursing
Are Investigators or their immediate family (spouse, parent, child, grandparent, or grandchild)
Have any serious, unstable medical illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease
Have severe allergies or multiple adverse drug reactions
Have a current or past history of seizures
Meet current DSM-IV criteria for anxiety or depression or illicit substance abuse in prior six months (these exclusions are feasible because, although the lifetime comorbidity of ADHD with these disorders is high, we and others have shown that the presence of these disorders at the time of ascertainment for adult ADHD studies is less than 10%)
Are judged by the study psychiatrist to be at serious suicidal risk
Have current or past diagnoses of schizophrenia or bipolar disorder
Have a history of hypersensitivity to amiloride or drug class members
Have a history of hyperkalemia, diabetes mellitus, renal disease or anuria
Have renal impairment Cr > 1.5; or
Are taking potassium supplements, aldosterone antagonists, tacrolimus or ACE inhibitors.
Study Locations And Contact Information
SUNY Upstate Medical University, Syracuse New York
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.